US 12,233,103 B2
Indoleamine 2,3-dioxygenase based immunotherapy
Mads Hald Andersen, Naerum (DK); and Per Thor Straten, Hvidovre (DK)
Assigned to IO Biotech ApS, Copenhagen (DK)
Filed by IO BIOTECH APS, Copenhagen (DK)
Filed on Apr. 10, 2023, as Appl. No. 18/298,263.
Application 18/298,263 is a continuation of application No. 17/721,577, filed on Apr. 15, 2022, granted, now 11,648,302.
Application 17/721,577 is a continuation of application No. 17/697,732, filed on Mar. 17, 2022, abandoned.
Application 17/697,732 is a continuation of application No. 16/261,114, filed on Jan. 29, 2019, granted, now 11,324,813, issued on May 10, 2022.
Application 16/261,114 is a continuation of application No. 15/231,075, filed on Aug. 8, 2016, granted, now 10,258,678, issued on Apr. 16, 2019.
Application 15/231,075 is a continuation of application No. 12/988,124, granted, now 9,433,666, issued on Sep. 6, 2016, previously published as PCT/DK2009/000095, filed on Apr. 17, 2009.
Claims priority of application No. 2008 00565 (DK), filed on Apr. 17, 2008.
Prior Publication US 2023/0233657 A1, Jul. 27, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/20 (2006.01); A61K 38/19 (2006.01); A61K 39/00 (2006.01); A61K 45/06 (2006.01); C12N 9/02 (2006.01)
CPC A61K 38/2013 (2013.01) [A61K 38/193 (2013.01); A61K 39/001154 (2018.08); A61K 45/06 (2013.01); C12N 9/0069 (2013.01); C12Y 113/11052 (2013.01); A61K 2039/5158 (2013.01); A61K 2039/55566 (2013.01); A61K 2039/572 (2013.01)] 19 Claims
 
1. A method of treating a cancer in a subject in need thereof, the method comprising administering to the subject, a composition comprising:
(i) a nucleic acid encoding a peptide fragment consisting of no more than 25 consecutive amino acids of indoleamine 2,3-dioxygenase (IDO) of SEQ ID NO: 1, wherein the consecutive amino acids comprise residues 199-207 of SEQ ID NO: 1 (SEQ ID NO: 6: Ala-Leu-Leu-Glu-Ile-Ala-Ser-Cys-Leu), wherein the peptide fragment is immunogenically active and is 13 to 25 amino acids in length.